Comparison of allogeneic stem cell transplantation, high‐dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia

Abstract

The three postremission treatment groups had comparable survival. Allogeneic SCT is associated with a prolonged FFS.